MONCTON, New Brunswick, March 19, 2018 (GLOBE NEWSWIRE) -- Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company discovering and developing targeted cancer therapeutics, is pleased to announce that Marc Rubin, MD and Vaughn Embro-Pantalony have been appointed to the Company’s Board of Directors, effective immediately.
“We are pleased to welcome Marc and Vaughn to the Board of Directors of Soricimed Biopharma Inc. Their pharmaceutical and financial experience will help the company as we move forward,” said Tom Reeves, Chairman of Soricimed. “We believe the combination of domestic and global business experience that they bring will be a significant asset to the Board. They bring a wealth of industry knowledge to our Company and both have strong track records as leaders in the Life Sciences sector. We look forward to leveraging their expertise as we move Soricimed forward.”
Dr. Rubin commented: “I am excited to join Soricimed’s Board. This is a unique opportunity to help shape a company with significant assets addressing a global unmet need.”
“I am thrilled to be joining Soricimed’s Board at this important time,” said Mr. Embro-Pantalony. “I look forward to working with the Company as we move further through our clinical development.”
Rick Pryde, a long-serving director of Soricimed will be stepping down from the Board. “Rick joined us as a board member when we were a young company,” said Jack Stewart, Founder and CSO. “The experience and insight he brought to us certainly helped shape our direction over the last years. Many thanks, Rick”.
About the New Board Members
Dr. Rubin brings extensive global pharmaceutical, biotech and financing experience to Soricimed. Currently Marc is Executive Chairman of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), after serving as its President and CEO. Dr. Rubin’s pharmaceutical experience includes being Head of Global Research and Development for Bayer Schering Pharma, as well as senior positions with global research and development as well as commercial responsibilities at GlaxoSmithKline. Dr. Rubin holds an M.D. from Cornell University Medical College and is board certified in internal medicine, medical oncology and infectious diseases.
Mr. Embro-Pantalony brings extensive pharmaceutical and biotech experience and a strong background in finance and business development. Currently Vaughn is a board member and former President and CEO of Microbix Biosystems Inc., a Canadian public biotech company (TSX:MBX). Prior to this Mr. Embro-Pantalony held V.P. Finance and CFO positions with Teva Novopharm, Ltd. and Bayer Healthcare in Canada. Mr. Embro-Pantalony holds an MBA from the University of Windsor and is a Fellow Chartered Professional Accountant.
About Soricimed Biopharma: Soricimed Biopharma Inc. is a private Canadian clinical-stage company developing novel cancer therapeutics and diagnostics. Soricimed’s drug candidates have demonstrated a capability to reduce cancer cell viability, induce apoptosis and to reduce human tumour volume while minimizing side-effects in classic animal and in vitro tumour models. Soricimed recently announced positive results indicating safety, tolerability and potential activity in a Multi-centre Phase I trial of SOR-C13 in subjects with advanced solid tumour cancers. Additionally, Soricimed obtained two orphan drug statuses for treatment of ovarian and for pancreatic cancers with SOR-C13. Privately held, Soricimed is funded through private investors and various programs from the Governments of Canada and New Brunswick. For more information please visit, www.soricimed.com.
For More Information:
Paul Gunn, President & CEO
Soricimed Biopharma Inc.
Source:Soricimed Biopharma Inc.